Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

NCT03748784 is registered in ClinicalTrials.gov with Adverum Biotechnologies, Inc. as lead sponsor.

NCT NCT03748784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03748784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration
Lead sponsor
Adverum Biotechnologies, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2018
Completion date
June 22, 2022
Enrollment
30 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration, wet age-related macular degeneration